Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsallcareadvantage SGLT2 Coverage Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 026.6

    Approval Criteria for formulary SGLT2 Inhibitors

    Customize your policy alerts

    Sign up for allcareadvantage Policy 026.6 alerts

    Get alerted when Policy 026.6 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines AllCare Advantage coverage, prior authorization, and renewal criteria for formulary and non-formulary SGLT2 inhibitor drugs for treatment of type 2 diabetes, including special considerations for heart failure and chronic kidney disease.

    Policy Summary
    Payerallcareadvantage
    PolicyApproval Criteria for formulary SGLT2 Inhibitors
    Policy CodePolicy 026.6
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 31, 2028
    Next Review DateMay 31, 2028
    Key ActionObtain prior authorization and document diagnosis of type 2 diabetes and metformin trial or contraindication; approvals up to 1 year.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 1 yearApproval length
    Metformin first-lineFirst-line requirement
    7 agentsAgents covered
    Stepwise criteriaDecision basis

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage and Exclusions

    Initial and Renewal Therapy

    Covered when ALL of the following are met according to the stepwise prior authorization flow:

    Initial Authorization

    • Non-preferred agent exceptions: A) Patient has heart failure and is requesting an SGLT2 with demonstrated cardiovascular benefit -> continue to cost/contraindication check; B) Patient has chronic kidney disease and is requesting an SGLT2 with demonstrated renal and cardiovascular benefits -> continue to cost/contraindication check; C) Preferred agent is contraindicated and the requested non-preferred SGLT2 is the lowest cost option -> Approve up to 1 year.

      If none of these exceptions apply -> Deny.

    Renewal Authorization: 1) Member met initial prior authorization criteria for the agent. 2) Recent chart notes support continuation of the medication.

    If both met -> Approve up to 1 year; otherwise -> Deny.

    Coverage of non-formulary SGLT2 inhibitors is allowed only when the requested use is consistent with FDA‑approved indications and there is documentation of treatment failure or contraindication to two formulary agents. This aligns with the policy requirement that non‑formulary agents be reserved for cases where formulary options have been tried and proven ineffective or cannot be used.

    Use of an SGLT2 inhibitor is not approved if the member has not trialed metformin or there is no documentation of a diagnosis of type 2 diabetes. Non‑preferred agents are denied unless one of the explicit exceptions applies: demonstrated heart failure or chronic kidney disease benefit for the requested agent, contraindication to the preferred agent, or the requested non‑preferred agent is the lowest‑cost option after contraindication is documented.

    Prior Authorization, Documentation, and Denials

    Prior Authorization

    Obtain prior authorization per stepwise criteria

    Prior authorization is required for all formulary and non‑formulary SGLT2 inhibitors and is granted only after the stepwise criteria in the policy are met; approvals may be issued for up to 1 year.

    • Follow the stepwise PA flow (diagnosis, metformin trial/contraindication, agent status, and any HF/CKD or cost checks).
    • Renewals follow the renewal path and require chart support of continued benefit.
    Step Therapy

    Require metformin trial and preferred‑agent failure for non‑preferred

    Members must have previously tried or currently be taking metformin; for non‑preferred agents, the member must have tried and failed a preferred formulary agent unless a specific exception applies.

    • Preferred formulary SGLT2s: approve if metformin trial/inadequate control or contraindication to metformin is documented.
    • Non‑preferred: require failure of preferred agent unless HF/CKD benefit, contraindication to preferred agent, or lowest‑cost non‑preferred applies.
    Documentation Required

    Submit chart documentation of diagnosis, metformin trial/contraindication, and renewal support

    Include chart notes that document a diagnosis of type 2 diabetes, evidence of a trial of metformin or a contraindication to metformin, and — for renewals — recent notes supporting continued benefit from the SGLT2 therapy.

    • Diagnosis documentation: chart notes confirming type 2 diabetes.
    • Metformin documentation: notes showing inadequate HbA1c on metformin or contraindication to metformin.
    • Renewal documentation: recent chart notes demonstrating ongoing medical necessity or clinical benefit.
    Denial Risk

    Requests lacking diabetes diagnosis, metformin trial, or renewal support will be denied

    Deny the request if there is no documentation of a type 2 diabetes diagnosis or if the member has not tried and failed metformin (unless contraindicated). Also deny renewals when recent chart notes do not support continued benefit.

    • Initial denials: absence of documented type 2 diabetes or failure to meet metformin trial/contraindication requirement -> Deny.
    • Renewal denials: failure to meet initial PA criteria at renewal or lack of recent notes supporting continuation -> Deny.
    Denial Risk

    Additional denial risks for HF/CKD requests and non‑preferred agents

    Deny when a patient with heart failure or chronic kidney disease requests an SGLT2 without demonstrated cardiovascular or renal benefit, or when a preferred agent is not contraindicated and a lower‑cost preferred agent is available.

    • HF/CKD exceptions: approval only if the requested SGLT2 has demonstrated cardiovascular (HF) or renal and cardiovascular benefits.
    • Cost/contraindication check: deny if preferred agent is not contraindicated and requested non‑preferred is not the lowest cost.

    Initial Authorization Criteria

    Initial Therapy

    Initial authorization criteria

    Initial agent criteria

    • Criteria #5-#7 (non-preferred): #5: If patient has heart failure and requests an SGLT2 with demonstrated cardiovascular benefit -> go to #7; otherwise deny. #6: If patient has chronic kidney disease and requests an SGLT2 with demonstrated renal and cardiovascular benefits -> go to #7; otherwise deny. #7: Is the preferred agent contraindicated and is the requested non-preferred SGLT2 the lowest cost option? If yes -> Approve up to 1 year; if no -> Deny.

      Coverage of non-formulary agents requires use consistent with FDA indications and failure/contraindication to 2 formulary agents (policy applies).

    Renewal (Continuation) Criteria

    Renewal Therapy

    Renewal criteria

    Renewal requirements: 1) Member met the PA criteria at initial authorization. 2) Recent chart notes support continuation of the medication.

    If both criteria are met -> Approve up to 1 year; if either is not met -> Deny.

    Step Therapy and Preferred Agent Requirements

    StepRequirementAction
    1
    Member must have previously tried or currently be taking metformin (trial of metformin with inadequate HbA1c control or documented contraindication)
    If metformin not tried or no documentation of type 2 diabetes → Deny

    Definitions and Indications

    inv-10: FDA approved indication — Type II diabetes (glucose lowering)
    FDA approved indicationType II diabetes (glucose lowering)
    Policy purposeDefines coverage process for SGLT2 inhibitors for treatment of Type 2 diabetes
    Clinical monitoring noteMonitor for ketoacidosis risk (pancreatic insulin deficiency, caloric restriction, alcohol abuse) and consider temporary discontinuation in precipitating situations (e.g., prolonged fasting, acute illness, surgery)
    Formulary coverage ruleCover preferred formulary SGLT2 for members who have tried or are currently taking metformin
    Non-preferred formulary exceptionsCover lowest-cost non-preferred formulary SGLT2 if member failed preferred agent, or if member has heart failure (agent with demonstrated CV benefit) or CKD (agent with demonstrated renal and CV benefits)
    Non-formulary requirementCoverage of non-formulary SGLT2 inhibitors requires FDA-consistent use and treatment failure or contraindication to 2 formulary agents

    Clinical Background

    Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors are FDA‑approved for glucose lowering in type 2 diabetes and certain agents have demonstrated cardiovascular and renal benefits. The policy requires monitoring for factors that predispose to ketoacidosis (for example, pancreatic insulin deficiency, prolonged fasting, or alcohol use) and consideration of temporary discontinuation in precipitating clinical situations. Approvals for SGLT2 inhibitors under the stepwise prior authorization flow are issued for up to 1 year when criteria are met.

    Policy Summary
    Payerallcareadvantage
    PolicyApproval Criteria for formulary SGLT2 Inhibitors
    Policy CodePolicy 026.6
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMay 31, 2028
    Next Review DateMay 31, 2028
    Key ActionObtain prior authorization and document diagnosis of type 2 diabetes and metformin trial or contraindication; approvals up to 1 year.
    SourceLink
    On This Page
    Coverage and ExclusionsPrior Authorization, Documentation, and DenialsInitial Authorization CriteriaRenewal (Continuation) CriteriaStep Therapy and Preferred Agent RequirementsDefinitions and IndicationsClinical Background